Clinical Trial Update: Denileukine Diftitox for Relapsed ALCL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating denileukin diftitox (Ontak) for relapsed Anaplastic Large-Cell Lymphoma has been withdrawn. The study sponsor is Columbia University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Columbia University | Conditions: Anaplastic Large-Cell Lymphoma | Phase 2 | Status: WITHDRAWN